Ion-682884
Web13 nov. 2024 · ION-682884-CS2 (EudraCT No: 2024-002835-27) is a Phase 3 global, double-blind, randomized, placebo-controlled study assessing the efficacy and safety of AKCEA-TTR-LRx (ION-682884) in hATTR-CM or ... Web29 mrt. 2024 · Drug Profile Eplontersen - Ionis Pharmaceuticals Alternative Names: AKCEA-TTR-LRx; ION-682884; ION-TTR-LRx; IONIS-TTR-LRx Latest Information Update: 29 …
Ion-682884
Did you know?
WebA Study to Assess the Long-Term Safety and Efficacy of ION-682884 in Patients With Hereditary Transthyretin-Mediated Amyloid Polyneuropathy This is a multicenter, open … Web12 jul. 2024 · Satisfactory completion of Treatment Period and the End of Treatment Visit of the Index Study (ION-682884-CS2) OR diagnosis of ATTR-CM and satisfactory …
WebTo evaluate the efficacy of ION-682884 after administration for 65 weeks, as compared to the historical control of the placebo cohort in the NEURO-TTR trial, based on the change … Web8 okt. 2024 · A Study to Assess the Long-Term Safety and Efficacy of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Patients With …
WebAims: Amyloidogenic transthyretin (ATTR) amyloidosis is a fatal disease characterized by progressive cardiomyopathy and/or polyneuropathy. AKCEA-TTR-L Rx (ION-682884) is a ligand-conjugated antisense drug designed for receptor-mediated uptake by hepatocytes, the primary source of circulating transthyretin (TTR). Enhanced delivery of the antisense … Web23 nov. 2024 · These antisense therapies rely on modified nucleotides sequences (single-strand DNA or RNA, both belonging to the antisense oligonucleotides family, or double-strand interfering RNA) to act specifically on pathogenic target nucleic acids, thanks to complementary base pairing.
Web15 apr. 2024 · Because ION-682884 is an antisense oligonucleotide similar to inotersen and because inotersen has been associated with thrombocytopenia and worsening renal …
WebThis trial is testing a new drug to see if it can slow or stop the progression of a disease called TTR amyloid cardiomyopathy. The disease is caused by a protein called … greenhouse builders north carolinaWebION-682884 reduces the level of TTR in the blood of animals and healthy volunteers tested to date. Reducing the amount of TTR in your blood may reduce the amount of amyloid … greenhouse builders coloradoWebEligible participants will receive ION-682884 once every 4 weeks for up to 157 weeks. Participants will also receive daily supplemental doses of the recommended daily … greenhouse buffet price 2015WebRx (ION-682884) is a ligand-conjugated antisense drug designed for receptor-mediated uptake by hepatocytes, the primary source of circulating transthyretin (TTR). Enhanced … green house buffalo nyWeb1 jul. 2024 · AKCEA-TTR-L RX (ION-682884) is an antisense oligonucleotide (ASO) that inhibits the production of TTR. It has a similar design and sequence as inotersen (the parent compound), but is conjugated to a triantennary N-acetyl galactosamine (GalNAc3) moiety for selective receptor-mediated delivery to hepatocytes, the principal source of systemically … fly ashtrayWeb31 okt. 2024 · ICH GCP; Register voor klinische proeven in de VS. Klinische proef NCT03728634; Evalueer de veiligheid en verdraagbaarheid, evenals de … greenhouse bubble wrap rollsWebApply to this Phase 3 clinical trial treating Hereditary Transthyretin-Mediated Amyloid Polyneuropathy. Get access to cutting edge treatment via Eplontersen, ION-682884. … fly ash tradução